



Company Announcement

Clinuvel's second regular investor update via teleconference

Dear Investors

The CEO of Clinuvel cordially invites you on Thursday, to participate in the second of our regular investor updates via teleconference. Topics will include the company's status quo and objectives for 2008

Our second investor update teleconference is scheduled for Thursday 22nd November, at 7.00 p.m. (Australian EDST) (8.00 a.m. GMT).

This is a bi-monthly activity. The teleconference will be recorded and made available on our website following the teleconference.

Investors are invited to use the International Toll Free Numbers provided below, and use **Conference Code 25461776**. Investors need to make themselves publicly known when participating in the conference call.

Due to a limited number of lines available, please aim to log in before the 7pm Australian EDST commencement time. Please follow instructions given. You will be asked to provide your full name and company, along with the Conference ID-No.

International Toll Free Dial-in Number(s):

Australia	1800701269	Korea (South)	0079861360703
Austria	0800296101	Malaysia	1800812564
Belgium	080073590	Netherlands	08000224523
Canada	18884473085	New Zealand	0800446041
China , NetCom Users	108006400084	Norway	80019205
China , Telecom Users	108002640084	Philippines	180011100434
Czech Republic	800142553	Portugal	800819455
Denmark	80887204	Singapore	8006163092
France	0800916748	South Africa	0800998026
Germany	08001821244	Spain	900996480
Hong Kong	800968831	Sweden	020795445
Hungary	0680018521	Switzerland	0800562703
India	0008001006444	Taiwan	00801615152
Indonesia	00180306130660	Thailand	00180061360689
Ireland	1800556432	United Arab Emirates	8000174259
Italy	800870537	United Kingdom	08082347860
Japan	00531250068	United States	18662421388

If have any further enquires please email investorrelations@clinuvel.com

Yours sincerely

Colin Mackie
Head of Corporate Development

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (ASX:**CUV**, XETRA/DAX:**UR9**, ADR:**CUVLY**) is an Australian biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a range of UV-related skin disorders as well as in cancer related treatments.

The five indications are:

Indication	Description	Clinical Trial Status
Polymorphic Light Eruption (PLE / PMLE)	Sun poisoning	Phase III trials began May 2007
Erythropoietic Protoporphyrria (EPP)	Absolute sun intolerance	Phase III trials began June 2007
Squamous Cell Carcinoma (SCC) and Actinic Keratosis (AK) in organ transplant patients	Non-melanoma skin cancers / precursor to skin cancers	Phase II trials planned to begin 2007
Solar Urticaria (SU)	Acute anaphylactic reaction to sun	Phase II trials planned to begin 2007
Phototoxicity associated with Photodynamic Therapy (PDT)	Photo-sensitivity associated with cancer treatment	Phase II trials planned to begin 2007

Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of CUV1647.

-END-

For more information contact:

Colin Mackie
Head of Corporate Development
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for CUV1647 is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia

T +61 3 9660 4900
F +61 3 9660 4999

clinuvel.com